Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recent clinical trials have used CXCR4 antagonists for the rapid mobilization of CD34(+) haemopoietic stem/progenitor cells (HSC/HPC) from the bone marrow to the blood in patients refractory to granulocyte-colony-stimulating factor (G-CSF). These antagonists not only mobilize non-cycling cells with a higher proportion of repopulating cells, but also enhance CD34(+) cell mobilization when used in combination with G-CSF. Here, we review the importance of CXCR4 and its ligand CXCL12 in haemopoiesis, and the potential roles of CXCR4 antagonists in the clinical HSC transplant setting.

Original publication




Journal article


Vox Sang

Publication Date





18 - 32


Amino Acid Sequence, Chemokine CXCL12, Clinical Trials as Topic, Granulocyte Colony-Stimulating Factor, Hematologic Diseases, Hematopoiesis, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Humans, Models, Biological, Models, Molecular, Molecular Sequence Data, Receptors, CXCR, Receptors, CXCR4, Recombinant Proteins, Sequence Homology, Amino Acid